spacer
home > ebr > spring 2002 > activating t cells with trojan horses - a novel approach to vaccine technology
PUBLICATIONS
European Biopharmaceutical Review

Activating T Cells With Trojan Horses - A Novel Approach to Vaccine Technology

The therapeutic antibody market has developed considerably since the first monoclonal antibody was approved in 1986 for preventing organ transplant rejection. Since then, revenues from therapeutic drugs have grown to more than US$2 billion in 2000, and are projected to reach US$8 billion by 2004 (1). From a pharmaceutical company's point of view, antibodies may present an attractive proposition as they have relatively short development times (six to seven years). Additionally, they are often less toxic and have more predictable pharmacological profiles than small molecule drugs. The current interest in vaccines and antibodies has also been driven by data from genomic and proteomic approaches, together with increasingly sophisticated methods for target antigen identification. Of course, target identification is merely the start of the process. In order to maintain the rate of market growth for this area, any reagents developed also need an efficient delivery method in order to elicit a strong, specific T cell response. This article will examine one way in which this can be achieved, via the targeting of antigens to antigen presenting cells (APCs), leading to enhanced antigen presentation and increased T cell activation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Ole Henrik Brekke, Director of New Technologies at Affitech AS, and Professor Inger Sandlie, Leader of the Antibody Engineering Group at the Department of Biology, University of Oslo

Dr Ole Henrik Brekke is Director of New Technologies at Affitech AS, a privately held biotechnology company based in Oslo, Norway. Ole has extensive experience in the field of antibody engineering and has made several major contributions to the understanding of how human immunoglobulins mediate their effector functions, with subsequent work published in leading scientific journals.
Professor Inger Sandlie leads the Antibody Engineering Group at the Department of Biology, University of Oslo, and is a member of Affitech's Scientific Advisory Board. She has made major contributions in the field of human antibody structure and her work has significantly improved our understanding of how antibodies mediate their normal effector functions. Her current research involves both phage display technology and advanced biocomputing tools in order to develop novel therapeutic agents.

spacer
Dr Ole Henrik
spacer
spacer
spacer
Professor Inger Sandlie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mr Turhan Ozen Chief Cargo Officer at Turkish Airlines elected to the International Air Cargo Association (TIACA) Committee

Turhan Ozen, serving as Chief Cargo Officer at the global brand Turkish Airlines, was elected to the International Air Cargo Association (TIACA) Committee, the joint voice of the industry that aims to enhance the air cargo profile with intensive efforts towards the global standards.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement